Document Detail

Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
MedLine Citation:
PMID:  11477439     Owner:  NLM     Status:  MEDLINE    
The study was designed to evaluate the efficacy and safety of an intensive, tri-alkylator conditioning regimen, consisting of thiotepa, busulfan and cyclophosphamide (TBC), prior to autologous hematopoietic cell transplantation in patients with multiple myeloma (MM) and to analyze factors associated with outcome. One hundred and twenty patients with MM received high-dose chemotherapy with TBC followed by autologous bone marrow (n = 24) or peripheral blood stem cell (PBSC) transplantation (n = 96). Fifty-four patients had chemosensitive disease and 66 had refractory disease at the time of transplantation. The overall response rate was 81% and the complete remission (CR) rate was 26%. Patients with chemosensitive disease had a CR rate of 52% vs 5% for patients with refractory disease. Multivariable analysis determined disease status at transplant as the factor most likely associated with long survival. Estimated median survival was 48, 35 and 9 months for patients with chemosensitive, primary refractory or disease in refractory relapse, respectively. Short interval from diagnosis to transplant among patients with primary refractory disease and younger age were also favorable prognostic factors for survival. Patients with refractory disease pre-transplant who achieved remission criteria rapidly after treatment had a worse outcome than the slow responders. Treatment-related mortality with the introduction of PBSC and better supportive care was 4.8%. In conclusion, TBC is an effective and relatively well-tolerated intensive conditioning regimen in patients with MM. A more favorable outcome was observed in patients with chemosensitive disease and with early treatment for primary refractory disease. TBC merits further study in these subgroups and comparison with alternative regimens in prospective studies is warranted.
A Shimoni; T L Smith; A Aleman; D Weber; M Dimopoulos; P Anderlini; B Andersson; D Claxton; N T Ueno; I Khouri; M Donato; M Korbling; R Alexanian; R Champlin; S Giralt
Related Documents :
2391329 - Acute renal failure due to leukaemic infiltration of kidneys.
18083329 - Therapeutic angiogenesis of bone marrow mononuclear cells (mncs) and peripheral blood m...
2566209 - Peripheral blood stem cell collection and use in hodgkin's disease. comparison with mar...
8775529 - Five year leukaemia-free survival of 72% and 77% for early stage acute and chronic myel...
9368339 - Peripheral blood progenitor cell transplantation as an alternative to autologous marrow...
7780689 - Detection of minimal residual disease in autologous grafts.
12970789 - Tolerance induction by costimulator blockade in 100 cgy treated hosts with varying degr...
11144989 - The tolerability of newer immunosuppressive medications in a patient with acute intermi...
336579 - A mathematical description of causative factors and prevention of elevated intraocular ...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Bone marrow transplantation     Volume:  27     ISSN:  0268-3369     ISO Abbreviation:  Bone Marrow Transplant.     Publication Date:  2001 Apr 
Date Detail:
Created Date:  2001-07-30     Completed Date:  2002-01-10     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  8702459     Medline TA:  Bone Marrow Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  821-8     Citation Subset:  IM    
Department of Blood and Bone Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  therapeutic use*,  toxicity
Busulfan / administration & dosage,  toxicity
Cyclophosphamide / administration & dosage,  toxicity
Graft Survival
Hematopoietic Stem Cell Transplantation / methods,  standards*
Middle Aged
Multiple Myeloma / diagnosis,  mortality,  therapy*
Remission Induction
Survival Analysis
Thiotepa / administration & dosage,  toxicity
Time Factors
Transplantation Conditioning / methods*,  standards
Transplantation, Autologous / methods,  standards
Reg. No./Substance:
50-18-0/Cyclophosphamide; 52-24-4/Thiotepa; 55-98-1/Busulfan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Degree of fatness after allogeneic BMT for childhood leukaemia or lymphoma.
Next Document:  Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem ce...